Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 22, 2011

Merck settles Vioxx lawsuit in the US

Merck has agreed to pay a $950m fine to settle criminal and civil charges that it misrepresented the safety of its anti-inflammatory drug Vioxx.

Merck has agreed to pay a $950m fine to settle criminal and civil charges that it misrepresented the safety of its anti-inflammatory drug Vioxx.

Under civil settlement agreements signed with the US and individually with 42 states, Merck will pay a $628.4m civil settlement to resolve allegations that it promoted the drug for treating rheumatoid arthritis before it had been approved for that indication by the US Food and Drug Administration.

The Justice Department also alleged that Vioxx, the generic name of which is rofecoxib, has been linked to the increased risk of heart attacks and strokes.

Merck pled guilty to a misdemeanour charge and will pay an additional $321.6m for introducing the misbranded drug into interstate commerce.

The charge closes a seven-year investigation in to the drug, which Merck pulled off shelves in 2004.

In a statement released on Tuesday, Merck executive vice-president Bruce Kuhlik said that the settlement does not mean the company admits liability or wrongdoing.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

"We believe that Merck acted responsibly and in good faith in connection with the conduct at issue in these civil settlement agreements, including activities concerning the safety profile of Vioxx," he said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU